Skip to search formSkip to main contentSkip to account menu
  • Publications
  • Influence
Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial.
TLDR
In patients with early RA, initial combination therapy including either prednisone or infliximab resulted in earlier functional improvement and less radiographic damage after 1 year than did sequential monotherapy or step-up combination therapy.
View on PubMed
Efficacy and toxicity of methotrexate in early rheumatoid arthritis are associated with single-nucleotide polymorphisms in genes coding for folate pathway enzymes.
TLDR
Patients with MTHfr 1298AA and MTHFR 677CC showed greater clinical improvement with MTX, whereas only the MTH FR 1298C allele was associated with toxicity, and MthFR genotypes may help determine which patients will benefit most from MTX treatment.
View on PubMed
Relationship between genetic variants in the adenosine pathway and outcome of methotrexate treatment in patients with recent-onset rheumatoid arthritis.
TLDR
Polymorphisms in the AMPD1, ATIC, and ITPA genes are associated with good clinical response to methotrexate (MTX) treatment, indicating that genotyping may help in the identification of patients who will benefit most from MTX treatment and may assist clinicians in making treatment decisions regarding patients with recent-onset RA.
View on PubMed
Changes in hand and generalised bone mineral density in patients with recent-onset rheumatoid arthritis
TLDR
The association between joint damage progression and both hand and generalised BMD loss in RA suggests common pathways between these processes, with hand B MD loss occurring earlier in the disease course than generalised bMD loss.
View on BMJ
A matrix risk model for the prediction of rapid radiographic progression in patients with rheumatoid arthritis receiving different dynamic treatment strategies: post hoc analyses from the BeSt study
TLDR
The matrix model visualises the risk of RRP for subpopulations of patients with recent-onset RA if treated dynamically with initial monotherapy or combination therapy, and was associated with a markedly reduced risk ofRRP.
View on BMJ
Cost-utility analysis of treatment strategies in patients with recent-onset rheumatoid arthritis.
TLDR
Initial combination therapy with infliximab for patients with recent-onset active RA resulted in significantly better quality of life than other strategies and should be preferred, according to the friction cost method.
View on PubMed
Autologous haematopoietic stem cell transplantation and other cellular therapy in multiple sclerosis and immune-mediated neurological diseases: updated guidelines and recommendations from the EBMT…
These updated EBMT guidelines review the clinical evidence, registry activity and mechanisms of action of haematopoietic stem cell transplantation (HSCT) in multiple sclerosis (MS) and other…
View on Springer
Exploratory analysis of four polymorphisms in human GGH and FPGS genes and their effect in methotrexate-treated rheumatoid arthritis patients.
TLDR
Frequency of two SNPs in FPGS and GGH genes and their associated with response to MTX in rheumatoid arthritis patients treated with MTX monotherapy are suggested not to be clinically important for MTX treatment outcome.
View on PubMed
Drug-free remission, functioning and radiographic damage after 4 years of response-driven treatment in patients with recent-onset rheumatoid arthritis
TLDR
In patients with recent-onset active RA, drug-free remission was achieved in up to 18% of patients, and DAS-driven treatment maintained clinical and functional improvement, independent of the treatment strategy.
View on BMJ
Aiming at low disease activity in rheumatoid arthritis with initial combination therapy or initial monotherapy strategies: the BeSt study.
TLDR
In patients with early, active RA, remarkable clinical improvement and suppression of joint damage progression can be achieved with frequent, objectively steered treatment adjustments.
View on PubMed
...
...
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License